NCT03907488 2026-04-13
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
20 trialsNCT05675410 2026-04-13
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT04685616 2026-03-30
RADAR
University College, London
Phase 3 Recruiting
NCT01712490 2026-02-27
A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Takeda
Phase 3 Completed
NCT03755804 2026-02-23
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT06831370 2026-02-23
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
Takeda
Phase 4 Recruiting
NCT03407144 2026-02-19
MK-3475-667
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT03033914 2026-02-17
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT06984146 2025-11-26
Nivo40-AVD for Advanced Classic Hodgkin Lymphoma
National Medical Research Radiological Centre of the Ministry of Health of Russia
Phase 2 Recruiting
NCT02979522 2025-11-10
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Takeda
Phase 1/2 Active not recruiting
NCT07013565 2025-10-21
ACCELERATE
New York Medical College
Phase 2 Active not recruiting
NCT03646123 2025-08-28
Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT03159897 2025-08-08
FIL Study on ABVD DD-DI as Upfront Therapy in HL.
Fondazione Italiana Linfomi - ETS
Phase 3 Completed
NCT00002462 2025-08-05
RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Active not recruiting
NCT00005584 2025-08-05
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Active not recruiting
NCT00049595 2025-08-05
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00379041 2025-08-05
Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Active not recruiting
NCT03331341 2025-08-05
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
University of Washington
Phase 1/2 Completed
NCT01868451 2025-07-09
Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting
NCT06377566 2025-04-20
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting